$282.55−3.20 (−1.12%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD
$282.70+0.15 (+0.05%)
After hours: Nov 16, 2026, 6:02 PM ET
Johnson & Johnson (JNJ) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineSteady: revenue compounds ~4.6%/yr (FY21→FY25), net margin 28.5%; free cash flow runs at 73% of net income. Check the accrual gap.
The four lines that matter · FY21–FY25
Revenue ($B)▲6.0%
94.2
FY21→FY25CAGR +4.6%/yr
Net income ($B)▲90.6%
26.8
one-off year: see footnoteCAGR +6.4%/yr
Free cash flow ($B)▼0.7%
19.7
FY21→FY25CAGR −0.1%/yr
Diluted EPS▲90.5%
11.03
buyback-liftedCAGR +9.0%/yr
What the receipts whisper · what a headline number hides
Share count
−9.1%
2.7bn → 2.4bn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
Capex
$4.8B
steady at 5.1% of revenue (+9.2% YoY).
Returns vs FCF
93%
$18.3B returned vs $19.7B of FCF in FY25. Buybacks + dividends covered by cash flow.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($B)
28¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 70.3% → 67.9%. Net margin 28.5% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 99,335.0 | 94,193.0 | 88,821.0 | 85,159.0 | 79,990.0 | 78,740.0 | ▲6.0% | +4.6% |
Cost of revenue | 32,222.0 | 30,256.0 | 27,471.0 | 26,553.0 | 24,596.0 | 23,402.0 | ▲10.1% | +6.6% |
Gross profit | 67,113.0 | 63,937.0 | 61,350.0 | 58,606.0 | 55,394.0 | 55,338.0 | ▲4.2% | +3.7% |
Research & development | 16,540.0 | 14,746.0 | 17,443.0 | 15,398.0 | 14,918.0 | 15,177.0 | ▼15.5% | −0.7% |
Selling, general & admin | 25,504.0 | 23,676.0 | 22,869.0 | 21,512.0 | 20,246.0 | 20,118.0 | ▲3.5% | +4.2% |
Total operating expenses | 42,375.0 | 38,650.0 | 40,546.0 | 37,399.0 | 35,439.0 | 35,504.0 | ▼4.7% | +2.1% |
Operating incomefeeds ROC rank | 24,738.0 | 25,287.0 | 20,804.0 | 21,207.0 | 19,955.0 | 19,834.0 | ▲21.5% | +6.3% |
Other income, net | −7,001.0 | 7,294.0 | −4,117.0 | −6,145.0 | −596.0 | −656.0 | — | — |
Pretax income | 17,737.0 | 32,581.0 | 16,687.0 | 15,062.0 | 19,359.0 | 19,178.0 | ▲95.2% | +14.2% |
Income tax | 1,642.0 | 5,777.0 | 2,621.0 | 1,736.0 | 2,989.0 | 1,377.0 | ▲120.4% | +43.1% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 16,095.0 | 26,804.0 | 14,066.0 | 35,153.0 | 17,941.0 | 20,878.0 | ▲90.6% | +6.4% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 6.58 | 11.03 | 5.79 | 13.72 | 6.73 | 7.81 | ▲90.5% | +9.0% |
Diluted shares (bn) | 2.45 | 2.43 | 2.43 | 2.56 | 2.66 | 2.67 | ▲0.0% | −2.4% |
| Margins | ||||||||
Gross margin51st pct in Healthcare | 67.6% | 67.9% | 69.1% | 68.8% | 69.3% | 70.3% | ▼1.2pp | −2.4pp |
Operating margin | 24.9% | 26.8% | 23.4% | 24.9% | 24.9% | 25.2% | ▲3.4pp | +1.7pp |
Net margin79th pct in Healthcare | 16.2% | 28.5% | 15.8% | 41.3% | 22.4% | 26.5% | ▲12.6pp | +1.9pp |
† TTM = trailing four quarters through 2026-09-27.FY21 effective tax rate was 7% vs a 15% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium, and 14 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-11 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Johnson & Johnson's revenue last fiscal year?
Johnson & Johnson reported revenue of $94.2B in fiscal 2025, up 6.0% from fiscal 2024.
What was Johnson & Johnson's net income?
Johnson & Johnson reported net income of $26.8B in fiscal 2025, a net margin of 28.5%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

